CVRX Share Price Performance
CVRX Community Fair Values
- US$11.00FV27.6% undervalued intrinsic discount16.50%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative2users have followed this narrative8 days ago author updated this narrative
Recent CVRX News & Updates
No updates
CVRx, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 04, 2025
- Earnings per share (EPS)
- -1.98
- Gross Margin
- 83.44%
- Net Profit Margin
- -97.49%
- Debt/Equity Ratio
- 71.1%
CVRx, Inc. Competitors
About CVRX
- Founded
- 2000
- Employees
- 206
- CEO
- WebsiteView website
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
U.S. Market Performance
- 7 Days: -0.6%
- 3 Months: 11.8%
- 1 Year: 16.8%
- Year to Date: 7.5%
The market has been flat in the last week, however the Materials sector is down 4.1%. Meanwhile, the market is actually up 16% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading